Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503210 | 0.81 | PTPN1 (0.38) | BCHEMEN1MAPK1KMT2A | |
| SCHEMBL1503131 | 0.80 | BCHE (0.39) | BCHEPPARGPPARACA12CA1 | |
| SCHEMBL1503245 | 0.77 | KMT2A (0.43) | MEN1MAPK1KMT2A | |
| SCHEMBL30193078 | 0.76 | KMT2A (0.40) | MEN1MAPK1KMT2AMMP1MMP13 | |
| SCHEMBL1503189 | 0.76 | KMT2A (0.40) | MEN1MAPK1KMT2AMMP1MMP13 | |
| SCHEMBL1503248 | 0.74 | ALDH1A1 (0.39) | MAPK1KMT2AMMP2 | |
| SCHEMBL30193010 | 0.74 | ALDH1A1 (0.39) | MAPK1KMT2AMMP2 | |
| SCHEMBL1503192 | 0.74 | ALDH1A1 (0.40) | CA1CA2MAPK1KMT2A | |
| SCHEMBL4316603 | 0.73 | PTPN1 (0.38) | BCHEMEN1MAPK1KMT2A | |
| SCHEMBL15746784 | 0.72 | BCHE (0.37) | BCHEPPARGPPARAMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | BCHE 809/4885PPARG 3257/4885PPARA 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.